The Latest Breaking News from Vertex

Given the growing demand for healthcare facilities, rapid integration of digital technology, and transformative biotechnology breakthroughs, the medical industry is poised for continued growth and profitability this year and beyond. Amid this, let’s find out why investors are flocking to medical stocks Vertex Pharmaceuticals (VRTX) and McKesson (MCK). Read more….

The stock market rally hit fresh highs, with the S&P 500 hit 5,000. Arm and Palantir skyrocketed, with several other AI plays running higher.

Vertex could bolster its cystic fibrosis franchise with a next-generation drug, analysts said Tuesday. But VRTX stock dipped.

Vertex's alternative to opioids is "not a game-changer," an analyst said Tuesday. But VRTX stock rebounded on the company's test results.

Crispr won its second gene-editing approval on Tuesday — two months ahead of time. But CRSP stock slipped, and VRTX stock rose minimally.

Vertex is the IBD Stock Of The Day as the maker of corporate tax compliance software expands its footprint with an acquisition.

Explore the cutting-edge research of three Breakthrough Prize laureates in Life Sciences, and the systemic issues that influence access to treatments for three diseases desperately looking for cures: Parkinson’s disease, cystic fibrosis, and cancer.

New gene therapies promise a cure for sickle cell disease but experts say they are out of reach in places that need them the most

Vertex solidified its potential for an alternative to opioids in pain treatment, an analyst said Wednesday. VRTX stock broke out.

Vertex stock rallied 13% Wednesday after reporting "statistically significant" results in a Phase 2 study for a pain drug.

Editorial: Patients are facing shorter lives as drug companies are demanding prices that health services here and in other countries cannot pay